APPROACH WITH CAUTION

No company is problem-free, but some fly more red flags than others. From a big bet on COVID-19 drugs that may or may not pay off, to a booming business still plagued by misinformation, consider these two players high-risk, high-reward. In October, the US Food and Drug Administration granted emergen...

Full description

Saved in:
Bibliographic Details
Published in:Fortune 2020-12, Vol.182 (4), p.132
Main Authors: Abril, Danielle, Aspan, Maria, Barrett, Eamon, Bellstrom, Kristen, Clifford, Lee, DeCarlo, Scott, Dunn, Katherine, Elegant, Naomi Xu, Fry, Erika, Hackett, Robert, Heimer, Matt, Kahn, Jeremy, Kowitt, Beth, Lev-Ram, Michal, McGregor, Grady, Nusca, Andrew, O'Keefe, Brian, Pressman, Aaron, Rapp, Nicolas, Shen, Lucinda, Wahba, Phil, Wieczner, Jen, Zillman, Claire
Format: Magazinearticle
Language:English
Subjects:
Product development
Strategic planning
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:No company is problem-free, but some fly more red flags than others. From a big bet on COVID-19 drugs that may or may not pay off, to a booming business still plagued by misinformation, consider these two players high-risk, high-reward. In October, the US Food and Drug Administration granted emergency use authorization for Celltrion's rapid COVID-19 testing kit, Sampinute, which promises to deliver results within 10 minutes and with a 94% sensitivity rate. The company is also developing a COVID-19 antibody treatment, to reduce the severity of the coronavirus once patients are infected, and has received South Korean regulatory approval to begin Phase III clinical trials of the drug. Facebook's underlying business remains strong. And new business opportunities continue to emerge: A global e-commerce strategy (including WhatsApp Pay) shows signs of promise, for example.
ISSN:0015-8259